The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

One-year clinical trial data for the next-generation, investigational, Sphere-360™ single-shot PFA catheter show impressive safety, performance, and efficiency results for paroxysmal Afib Dual-energy ...

The US Food and Drug Administration has approved a third pulsed-field ablation system, one that can also deliver radiofrequency energy, for the treatment of atrial fibrillation (AF), device maker ...

Medtronic plc MDT recently announced the receipt of a CE Mark for the Affera Mapping and Ablation System to treat atrial arrhythmias. The system includes the Sphere-9 Catheter and the Affera Prism-1 ...

Acquisition adds mapping and navigation platform to company's cardiac ablation portfolio and brings an integrated system of diagnostic and therapeutic tools to address a broad spectrum of arrhythmias ...

After Medtronic's Sphere-9 catheter is threaded through the veins to reach the heart, it automatically begins transmitting information to the connected navigation system to build electro-anatomical ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced strategic investments in two privately held companies focused on the development of intracardiac echocardiography ...

HRS late breaking data: SPHERE Per-AF trial demonstrates novel all-in-one system delivers exceptional results, plus increased efficiency and improved quality of life "These are excellent results for ...

Medtronic is acquiring Affera Inc., a medical technology company focused on treating cardiac arrhythmias, for $925 million. While Medtronic declined Monday to share the sale price, analysts at Piper ...

Medtronic plans to acquire Affera, a private medical technology company, for $925 million in a move to expand its portfolio of advanced ablation products as physicians see more patients with cardiac ...